惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

V
Visual Studio Blog
U
Unit 42
让小产品的独立变现更简单 - ezindie.com
让小产品的独立变现更简单 - ezindie.com
The GitHub Blog
The GitHub Blog
Microsoft Azure Blog
Microsoft Azure Blog
有赞技术团队
有赞技术团队
Stack Overflow Blog
Stack Overflow Blog
爱范儿
爱范儿
博客园 - 司徒正美
Vercel News
Vercel News
I
InfoQ
GbyAI
GbyAI
C
Check Point Blog
B
Blog RSS Feed
Martin Fowler
Martin Fowler
B
Blog
MyScale Blog
MyScale Blog
腾讯CDC
博客园 - Franky
Blog — PlanetScale
Blog — PlanetScale
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
Hugging Face - Blog
Hugging Face - Blog
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
博客园 - 三生石上(FineUI控件)

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
AbbVie Inc. (ABBV) M&A Call Transcript
SA Transcripts · 2026-06-23 · via All Articles on Seeking Alpha

AbbVie Inc. (ABBV) M&A Call June 22, 2026 9:00 AM EDT

Company Participants

Elizabeth Shea - Senior Vice President of Investor Relations
Robert Michael - CEO & Chairman of the Board
Roopal Thakkar - Executive VP of Research & Development and Chief Scientific Officer
Scott Reents - Executive VP & CFO
Jeffrey Stewart - Executive VP & Chief Commercial Officer

Conference Call Participants

Christopher Schott - JPMorgan Chase & Co, Research Division
Terence Flynn - Morgan Stanley, Research Division
Vamil Divan - Guggenheim Securities, LLC, Research Division
Mohit Bansal - Wells Fargo Securities, LLC, Research Division
Michael Yee - UBS Investment Bank, Research Division
Jason Gerberry - BofA Securities, Research Division
Evan Seigerman - BMO Capital Markets Equity Research
David Amsellem - Piper Sandler & Co., Research Division
David Risinger - Leerink Partners LLC, Research Division
Louise Chen - Scotiabank Global Banking and Markets, Research Division
Steve Scala - TD Cowen, Research Division
Matthew Phipps - William Blair & Company L.L.C., Research Division

Presentation

Operator

Good day, and thank you for standing by. Welcome to the AbbVie Investor and Analyst Conference call. [Operator Instructions] As a reminder, this call is being recorded.

I would now like to introduce Ms. Liz Shea, Senior Vice President, Investor Relations.

Elizabeth Shea
Senior Vice President of Investor Relations

Good morning, and thank you for joining us for this special conference call to discuss AbbVie's acquisition of Apogee Therapeutics, which we announced earlier today. Joining me on the call today are Rob Michael, Chairman of the Board and Chief Executive Officer; Roopal Thakkar, Executive Vice President, Research and Development, Chief Scientific Officer; and Scott Reents, Executive Vice President, Chief Financial Officer. Joining us for the Q&A portion of the call is Jeff Stewart, Executive Vice President and Chief Commercial Officer. We have posted a set of slides with additional background for your reference, which can be found on the AbbVie investor website.